Loader

Pathways

PathWhiz ID Pathway Meta Data

PW058511

Pw058511 View Pathway
drug action

Talastine H1-Antihistamine Action

Homo sapiens
Talastine is a first-generation alkylamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW132539

Pw132539 View Pathway
metabolic

Talazoparib Drug Metabolism

Homo sapiens
Talazoparib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Talazoparib passes through the liver and is then excreted from the body mainly through the kidney.

PW146446

Pw146446 View Pathway
drug action

Talazoparib Drug Metabolism Action Pathway

Homo sapiens

PW127729

Pw127729 View Pathway
drug action

Talbutal Action Pathway

Homo sapiens
Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. It is a nonselective central nervous system (CNS) depressant. As with other barbiturates, talbutal is capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. Barbiturates may also induce anesthesia at sufficiently high therapeutic doses. Talbutal binds to GABAA receptors at a distinct binding site associated with a Cl- ionopore of the receptor. Upon binding, talbutal increases the duration of time for which the Cl- ionopore is open, leading to prolonged inhibitory effect of GABA at the postsynaptic thalamic neuron. Talbutal is a potentiator of the GABA(A) alpha-1 through alpha-6 subunits. Some side effects of using Talbutal may include drowsiness, loss or coordination, nausea, and insomnia.

PW132536

Pw132536 View Pathway
metabolic

Talbutal Drug Metabolism

Homo sapiens
Talbutal is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Talbutal passes through the liver and is then excreted from the body mainly through the kidney.

PW144434

Pw144434 View Pathway
drug action

Talbutal Drug Metabolism Action Pathway

Homo sapiens

PW146181

Pw146181 View Pathway
drug action

Talc Drug Metabolism Action Pathway

Homo sapiens

PW000250

Pw000250 View Pathway
drug action

Tamoxifen Action Pathway

Homo sapiens
Tamoxifen is a selective estrogen modulator (SERM) used in the treatment of estrogen-sensitive breast cancer. Tamoxifen itself only has weak anti-estrogen effects and must be converted into more active metabolites to have therapeutic activity. Metabolism takes place in the liver and is carried out primarily by cytochrome P450 enzymes. Tamoxifen is hydroxylated by CYP2D6 and demethylated by CYP3A4 and CYP3A5, producing the active metabolites 4-hydroxytamoxifen and endoxifen. These metabolites inhibit estrogen binding to estrogen receptors in breast cancer cells, which in turn inhibit tumour growth.

PW126183

Pw126183 View Pathway
drug action

Tamoxifen Anti-Cancer Action Pathway

Homo sapiens
Tamoxifen is an anticancer drug that is a selective estrogen receptor modulator also known as a non-steroidal anti-estrogen. It is used to treat estrogen receptor positive breast cancer as well for reducing the risk of invasive breast cancer post surgery. It is also prescribed as a prophylaxis for women with a high risk of breast cancer. It's often prescribed alone or possible as an adjuvant in other treatments. Tamoxifen's mechanism of action works by inhibiting the growth of tumor cells while also promoting apoptosis. It competitively inhibits estrogen/estradiol binding to its receptor which prevents the coactivator from binding to the receptor-tamoxifen complex in the nucleus. This prevents transcription of the estrogen target genes decreasing the production of tumor growth factor alpha and insulin-like growth factor 1 while increasing sex hormone binding globulin. Tamoxifen is also shown to induce apoptosis in estrogen receptor positive cancer cells. The action might be due to the inhibition of protein kinase C (PKC) which inhibits DNA synthesis. Overdose of tamoxifen leads to acute neurotoxicity seen by tremors, hyperreflexia, unsteady gait, and dizziness. Tamoxifen is usually administered in an oral form in a tablet or solution form.

PW144787

Pw144787 View Pathway
drug action

Tamoxifen Drug Metabolism Action Pathway

Homo sapiens